1. Swine Coronaviruses {#sec0005}
======================

Coronaviruses were first described in the mid-1960s and subsequently isolated from a number of species including man, mice, swine and chicken. These viruses share a common morphological characteristic, a fringe of club-shaped projections, 12--24 nm long, around a pleomorphic 60--220 nm viral particle, having a resemblance to a solar corona ([@bib0190]). Coronaviruses infect humans and various animal species, causing respiratory, gastrointestinal and neurological diseases as well as hepatitis. Prominent examples include the severe acute respiratory syndrome virus (SARS-CoV), middle-eastern respiratory syndrome virus (MERS-CoV) and the feline infectious peritonitis virus (FIPV), to name a few.

Swine coronaviruses can be divided into respiratory (PRCoV) and enteropathogenic coronaviruses such as transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV) and porcine deltacoronavirus (PDCoV). The latter have similar epidemiological, clinical and pathological features. The family *Coronaviridae* is currently divided into four genera: *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus* and *Deltacoronavirus*. TGEV and PEDV belong to the *Alphacoronavirus* genus, whereas PDCoV belongs to genus of *Deltacoronaviruses*.

Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses with the largest RNA genome of approximately 30 kb reported to date. The genomic RNA includes 5′ and 3′ untranslated regions (UTR), and it is capped and polyadenylated. Open reading frame (ORF) 1a and ORF1ab occupy the 5′ two-thirds of the genome and encode two replicase polyproteins (pp1a and pp1ab). Expression of pp1ab protein requires a ribosomal frameshift during translation of the genomic RNA. Produced polyproteins are proteolytically cleaved into 16 nonstructural proteins, nsp1 through nsp16 by the proteinase activity of nsp3 and nsp5. The 3′-proximal one-third of the genome encodes four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Some betacoronaviruses have an additional membrane protein, hemagglutinin esterase (HE). Interspersed between these genes are genes encoding accessory proteins. The number of these genes varies between different coronaviruses. For instance, TGEV has 3 accessory genes, PDCoV has 2, whereas PEDV has only one ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Genome organization of swine enteric coronaviruses TGEV, PEDV, and PDCoV. Genes for structural proteins are presented in yellow. Putative accessory genes are shown in green. Nonstructural proteins encoded by ORF1a/b are presented in blue. TGEV, transmissible gastroenteritis coronavirus; PEDV, porcine epidemic diarrhea virus; PDCoV, porcine deltacoronavirus; S, spike; E, envelope; M, membrane; N, nucleocapsid. Genomes have 5′ cap and 3′ poly A tail.Fig. 1

The viral RNA genome is packaged by the N protein into a helical nucleocapsid. In addition to the structural role, the N protein prolongs S-phase cell cycle, induces endoplasmic reticulum stress, up-regulates interleukine-8 expression and antagonizes type I interferon production ([@bib0085], [@bib0345]). The S protein, which forms peplomers on the virion surface, mediates binding to host receptors and membrane fusion. It can be divided into S1 and S2 domains. In some coronaviruses the S protein is processed into S1 and S2 fragments by cellular proteases or trypsin ([@bib0020], [@bib0330]). The S protein is a major target for virus neutralizing antibodies ([@bib0055], [@bib0250]). The M protein is the most abundant virion component and also contains conserved linear B-cell epitopes ([@bib0365]). The E protein is responsible for the assembly of virion, and it causes endoplasmic reticulum stress and interleukin-8 expression up-regulation ([@bib0340]). Accessory genes are dispensable for virus growth *in vitro*, but they may play an important role in the virus survival in the infected host. Indeed, the product of the TGEV accessory gene ORF7 reduces the expression of genes involved in the antiviral defense of the immune system, e.g. the interferon response, and inflammation ([@bib0080]). The ORF3 protein of PEDV functions as an ion channel, and it is thought to be related with virulence of PEDV ([@bib0300], [@bib0315]). One of the PEDV non-structural proteins, nsp1, was shown to be a type I interferon suppressor ([@bib0370]). Interestingly, PDCoV lacks the nsp1 gene.

2. Pathogenesis and clinical disease {#sec0010}
====================================

Coronaviruses target predominantly type I and II pneumocytes (PRCoV) or villous- and crypt enterocytes in the intestine (TGEV, PEDV and PDCoV). PEDV also infection Goblet cells in the small intestine ([@bib0125]). In addition, infection of alveolar macrophages and *lamina propria* macrophages has been shown for some but not all swine coronaviruses ([@bib0150], [@bib0230]). Entrance of the virus into the target cells is mediated by a series of receptor ligand interactions including heparin sulfate ([@bib0120]) and aminopeptidase N (APN) ([@bib0070], [@bib0170]). Importantly, the expression levels of aminopeptidase N appear to correlate with the level of infection, at least for PEDV. The higher the expression levels the more severe is the infection ([@bib0170], [@bib0360]). As a result, it may be perceivable that piglets born with lower APN levels in the brush border may be more resistant to PEDV than piglets with higher levels.

Enteric infections with TGEV and PEDV are characterized by severe diarrhea, vomiting and dehydration with high morbidity and mortality especially in piglets less than two weeks of age. In contrast, infections with respiratory coronaviruses cause very mild and transient disease in pigs of all ages, which often get unnoticed by the producer. Unless complicated by concurrent infections, PRCoV infections are only short lasting with temporary phases of coughing and respiratory distress. However, PRCoV can become a more significant problem during co-infections with other pathogens such as the porcine reproductive and respiratory syndrome virus PRRSV ([@bib0130]).

Infection of enterocytes with PEDV results in villous atrophy which can lead to malabsorption, diarrhea and anorexia. Within 24--48 h post infection, vomiting may occur, which typically does not last longer than 2--3 days post infection. Diarrhea can be found within 24 to 36 h post infection depending on the dose of the virus and the age of the piglets. Diarrhea typically lasts for about 5-8 days, but can last longer, and results in severe weight loss that often cannot be made up during the normal production cycle. Viral shedding is highest between days 3--5, but can last for days to weeks post infection. Surviving piglets start to recover around 6--8 days post infection, typically around the same time when proliferation of the crypt epithelium and regeneration of the villi occurs. Similarly, TGEV infects villous enterocytes and causes disease that clinically is indistinguishable from PEDV. Mortality rates are highest in young piglets, often reaching about 100%. In contrast, infection with PDCoV causes milder infections in piglets between 3 and 5 weeks of age. Diarrhea, vomiting and anorexia can be found in infected animals. In general, infected animals display much milder signs compared to infections with PEDV and TGEV.

3. Immunity to swine coronaviruses {#sec0015}
==================================

The innate immune response to enteric coronaviruses in pigs is characterized by a rapid antiviral response in the intestine, including the release of interferons, nuclear factor кB and other antiviral molecules ([@bib0065], [@bib0125], [@bib0275]). Pigs can produce three types of interferons ([@bib0280]): Type I interferons include well known interferons such as interferon α and β (IFN-α/β) and in pigs are encoded by as many as 17 different genes. The only type II interferon in pigs is IFN-ɣ. Type III interferons include IFN-λ1 (interleukin 29; IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B) and IFN-λ4 ([@bib0140], [@bib0235], [@bib0240], [@bib0295], [@bib0360]). Their functions are unknown in pigs. Especially type I and III interferons are used by the host to counteract viral infections. In response, most viruses including PEDV and TGEV have developed strategies to evade and interfere with the interferon response. Several viral proteins, including structural and non-structural proteins have been identified for PEDV and TGEV that can suppress the interferon response. For an excellent review on the evasion of immunity by porcine coronaviruses please see ([@bib0360]).

The adaptive immune response to swine enteric coronaviruses is based on secretory antibodies and cytotoxic T cells. These include secretory IgA antibodies (SIgA) that are produced by antibody-secreting cells in the *lamina propria* of the mucosal tissues and systemic antibodies such as IgG and IgM are found in serum and interstitial tissues and some isotypes can be transsudated across the mucosal epithelium into the lumen ([@bib0065], [@bib0110]). The cellular response to swine coronaviruses is characterized by T helper cells that are supporting the production of antibodies and cytotoxic T cells that are targeting virus infected epithelial cells. In pigs, these are predominantly ɣɗ-cells, most of which can be found within the intraepithelial layer ([@bib0045]). The majority of T cell epitopes are located in the Spike and nucleoprotein of coronaviruses ([@bib0060], [@bib0265], [@bib0290]). Additionally, CD8 T cell epitopes have been found in the membrane protein of the human SARS-CoV ([@bib0350])

In neonatal piglets, the main mechanism of protection is mediated by lactogenic immunity. During lactation, SIgA, IgG and IgM are passively transferred to the piglet via colostrum and milk ([@bib0030], [@bib0255], [@bib0260], [@bib0270]). Colostrum contains predominantly IgG, which is transudated from sow serum and absorbed by the piglet within the first 24--48 h of life. Secretory IgA is predominantly found in milk, after transitioning from colostrum to milk around 3--4 days of age ([@bib0145]). SIgA is produced by antibody secreting cells in the mammary gland, and it was shown many years ago by Bohl and Saif ([@bib0035]) that these cells migrate from the gut to the mammary gland at the end of pregnancy. This was confirmed by others in a variety of species and chemokines such as CCL28 and others have been found responsible for recruiting these antibody secreting cells to the mammary gland ([@bib0050], [@bib0155], [@bib0200], [@bib0205], [@bib0335]). Thus, in order to enhance the level of maternal immunity the oral route seems to be the most obvious choice for vaccinating the sow. Indeed, most vaccines for enteric coronaviruses are designed to induce lactogenic immunity by vaccinating the sow, however, most of them are administered via systemic injection. In the absence of effective vaccines for PEDV, many producers are currently using a lock-down of the barn combined with feeding back infectious live virus to pregnant sows. However, the duration of immunity often does not extent more than a few years ([Table 1](#tbl0005){ref-type="table"} ), depending on the type of vaccine being used with live vaccines typically providing longer lasting immunity. Even after feed-back, immunity starts to wane after a relatively short period of time, often even less than a few months. For an excellent review of the role of lactogenic immunity for PEDV see ([@bib0145]). In addition to antibodies, the colostrum also contains innate effector molecules such as defensins and antimicrobial peptides, interleukins and cytokines ([@bib0015], [@bib0105], [@bib0180], [@bib0220], [@bib0270]).Table 1Vaccine strategies for swine enteric Coronaviruses.Table 1Vaccine typeDevelopmentAdvantagesDisadvantagesCoronavirus antigenInactivated virus\
([@bib0010], [@bib0090], [@bib0025])Virions are inactivated with chemicals.Easy to prepare; cannot cause disease if properly inactivated.Can induce Th2-skewed immune response; needs adjuvant.Whole virusLive-attenuated virus\
([@bib0380], [@bib0285])Genomes are mutated using multiple passages in Vero cells.Inexpensive; strong cellular and humoral immune responses; can be given orally.Reversion to virulence; can still cause some disease; protection is dose dependent.Whole virusViral vectored\
([@bib0355], [@bib0310]).Unrelated viral genome (Poxvirus, Adenovirus) engineered to express the gene of interest.Strong cellular and humoral immune responses; intrinsic adjuvant properties; can be given orally.Preexisting immunity against vector virus.Spike proteinSubunit\
([@bib0225], [@bib0185], [@bib0005])Antigen is expressed in mammalian, baculovirus, yeast or plant cells.Cannot cause disease from viral infection; can generate high-titer neutralizing antibodies.Expensive; needs adjuvant; protection can be incomplete.Spike proteinDNA vaccines\
([@bib0375], [@bib0195])Genes encoding antigens are cloned into plasmid expression vector.Cannot cause disease from viral infection; can be given orally when introduced into *Lactobacillus* or *Salmonella*.Th1-skewed immune response when used alone.Spike, nucleocapsid or membrane proteinsViral replicating particles vaccine\
([@bib0210], [@bib0215])Replicon RNA containing gene of interest is packaged into alphavirus virion particles.Cannot cause disease from viral infection; intrinsic adjuvant properties; high level of antigen expression.Oral delivery has not been demonstrated.Spike protein

The level of cross-protection is somewhat unclear for coronaviruses. For PEDV, Goede et al. reported that 3-day old piglets born to sows that had been infected with a mild strain of PEDV seven months previously, were protected against infection with a more virulent strain of PEDV ([@bib0095]). In this experiment the sows were challenged with a more virulent PEDV virus at day 109 of gestation, and orally re-challenged when the piglets were three days old. None of the sows displayed significant clinical symptoms. The piglets were orally challenged with 1 ml of mucus scrapings of the more virulent PEDV. While mortality and morbidity rates varied significantly amongst the piglets in each group, the overall morbidity and mortality was reduced in piglets born to sows that had been pre-exposed to PEDV.

4. Vaccines for TGEV and other coronaviruses {#sec0020}
============================================

In the 90s, TGEV was responsible for severe economic losses around the globe. Several vaccine technologies were developed and commercialised. By administration to sows, the importance of lactogenic immunity was established ([@bib0040], [@bib0260]). However, with a disappearance of the disease in many parts of the world, fewer vaccines are now commercially available in North America and Europe ([Table 2](#tbl0010){ref-type="table"} ). Most current commercial TGEV vaccines are live attenuated vaccines that are given to the sow during gestation in order to provide lactogenic immunity to the newborn piglet. These vaccines are often available as bi- or trivalent vaccines combined with rotavirus, PEDV and/or *Escherichia coli*. Experimental vaccines include novel DNA vaccines, vectored vaccines and recombinant vaccines ([Table 1](#tbl0005){ref-type="table"}). For example, the porcine adenovirus was used to deliver the TGEV spike protein ([@bib0310]). Yuan et al. used the swine pox virus to express the A epitope of the spike protein ([@bib0355]). DNA plasmids were generated for both PEDV and TGEV for the development of a DNA vaccine ([@bib0195]). Recombinant proteins (spike and nucleocapsid) have been extensively evaluated as recombinant vaccine following expression in bacteria, yeast and plants. Many of these are being assessed for their potential to mucosal immunity after oral administration.Table 2Vaccines for TGEV and PEDV.Table 2VirusRegion/countryVaccines in developmentCommercial vaccinesTGEVNorth AmericaRecombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccineLive attenuated vaccines (mono, bi- and trivalent for TGEV, rota and *E.coli*)EuropeRecombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccineLive attenuated vaccines (mono, bi- and trivalent for TGEV, rota and *E.coli*)AsiaRecombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccineInactivated vaccines (mono, bi- and trivalent for TGEV, rota, PEDV and/or E.coli); live attenuated trivalent TGEV, PEDV and porcine rotavirus (China)PEDVNorth AmericaRecombinant proteins expressed in yeast and baculovirus; DNA vaccine; infectious clone for live-attenuated vaccineInactivated vaccine; Recombinant alphavirus-based vaccineEuropeDNA vaccineInactivated vaccinesAsiaRecombinant vaccines expressed in baculovirus, yeast, plants*, Lactobaccilus case*i, *Salmonella* Typhimurium and othersInactivated bi-valent TGEV and PEDV vaccine (China; strain CV777); Live attenuated tri-valent TGEV, PEDV and porcine rotavirus (China; PEDV strain CV777); Live attenuated vaccine (Japan; PEDV strain 83P-5; South Korea; PEDV strains SM98-1 and DR-13, Philippines, PEDV strain DR13); Inactivated vaccine (South Korea, PEDV strain SM98-1)

5. Vaccines for PEDV in North America {#sec0025}
=====================================

The first vaccine for PEDV in the US was developed by Harrisvaccines™ in Iowa, and conditionally licensed in 2013. The vaccine, initially called iPED vaccine, was based on a truncated version of the PEDV spike gene produced in the SirraVax℠ RNA Particle Technology platform ([@bib0215]), which is based on the a pVEK replicon vector derived from the Venezuelan equine encephalitis virus. The technology is a propagation defective, single cycle RNA particle technology that is believed to target dendritic cells. A longer version of the spike genes was codon optimized and used in the second-generation vaccine called iPED plus, which now is commercially available as Porcine Epidemic Diarrhea Vaccine, RNA (PED RNA). The vaccine induced immunity in young pigs after two doses given intramuscularly in a three-week interval. Vaccinated weaned pigs when challenged with homogenized gut tissue from a clinical isolate displayed significantly reduced severity of clinical signs (diarrhea) and reduced viral shedding for the first 72 h ([@bib0210]). Vaccine efficacy was further tested in naïve sows. After three vaccinations at 8, 5, and 1 weeks pre-farrowing piglets from both groups were challenged between 2 and 6 days of age with 10^3^ TCID~50~ (PEDV/CO/2013). Average litter mortality in the control group was 91%, while average mortality in the vaccinated groups was 69% ([@bib0075]). Similar results were found in sows previously exposed to PEDV. After oral challenge of piglets within the first week average litter mortality was reduced from 59% in the control group to 45% in the vaccinated group. Finally, [@bib0100] evaluated the vaccine in 80 sows that had been previously exposed to PEDV. Vaccination induced higher titers against the S1 protein in the colostrum of vaccinated sows and reduced overall pig mortality by 3% ([@bib0100]).

A second vaccine for PEDV in the US was developed by Zoetis and made commercially available in 2014 under a conditional license. The vaccine consists of an inactivated whole virus formulated with an adjuvant. The vaccine was tested in PEDV negative sows, which were vaccinated twice, 3 weeks apart, with the vaccine (n = 23) or an adjuvant placebo (n = 3). The vaccine was safe and immunogenic and induced neutralizing antibodies to both the whole virus and the spike protein ([@bib0090]). The vaccine was also tested under field conditions in a PEDV positive commercial herd. Sows (n = 120) were vaccinated at 5- and 2 weeks pre-farrowing, control sows (n = 120) received placebo. Vaccination resulted in reduction of pre-weaning mortality due to PEDV from 6.3% in piglets born to control sows versus 0.6% in piglets born to vaccinated sows. Vaccination resulted in about 3 times higher neutralization antibody titers compared to the control group, and an additional 1.8 pigs per sows survived ([@bib0245]).

A third vaccine was recently developed by the Vaccine and Infectious Disease Organization-InterVac in Canada. The vaccine is based on inactivated virus formulated with an adjuvant. When administered to seronegative sows 4 and 2 weeks prior to farrowing, high levels of neutralizing antibodies against PEDV were found in colostrum and milk, as well as in the serum of piglets born to vaccinated sows. Piglets were orally infected at 5 days of life with 300 pfu of PEDV isolate CO 025. It was found that 95% of all piglets (n = 83) born to vaccinated sows survived the infection and showed significantly reduced clinical symptoms, weight loss and viral shedding. In contrast, all piglets from unvaccinated sows displayed severe clinical symptoms including weight loss and dehydration, and 50% of these piglets died within 6 days post infection. These results were confirmed in two additional clinical trials. A large field trial involving \> 600 sows was performed in three commercial units in Saskatchewan, Canada to assess the vaccine in different genetics, health statuses and management systems. The vaccine demonstrated to be completely safe to use; no adverse events including injection site reactions and reproductive complications were observed. Vaccine efficacy was evaluated in 8% of these animals by transporting the pregnant sows a week before farrowing to the VIDO-InterVac high containment facility. Following oral challenge at 5 days of age, survival was significantly higher in piglets born to vaccinated sows than those from control sows ([@bib0025]). The assessment of duration of immunity is currently ongoing. In addition, an affinity tagged PEDV S1 protein was expressed in the HEK293 system to be used as subunit vaccine. When administered to pregnant sows the vaccine partially protected newborn piglets against infection with PEDV ([@bib0185]).

6. PEDV vaccines in Asia {#sec0030}
========================

Since early 1980s, PEDV outbreaks have been reported in several Asian countries, including China, Japan, Thailand, Taiwan, the Philippines, South Korea and Vietnam. In October 2010, a large-scale outbreak of severe PEDV was reported in China ([@bib0320]). In late 2013, PEDV outbreaks occurred in Japan, South Korea and Taiwan ([@bib0160]). Phylogenetic analysis of PEDV full-length genomic sequences reveals that PEDV can be genetically divided into 2 groups: G1 (classical) and G2 (field epidemic or pandemic). Each group can be further divided into two subgroups: 1a and 1b, 2a and 2b, respectively. It is also possible that the low to moderate effectiveness of current PEDV vaccines are due to genetic differences between vaccine and field epidemic strains ([@bib0135]).

For disease control, an inactivated bivalent TGEV and PEDV vaccine was introduced in China in 1995. In March 2015, a trivalent attenuated vaccine (PEDV, TGEV and porcine rotavirus) was also approved. All these vaccines were based on the classical CV777 (G1-a) strain that can be grown to high titers in green monkey kidney Vero cells. There are no data published on the efficacy of these vaccines. However, de Arriba et al. ([@bib0380]) orally inoculated 11-day-old conventionally reared piglets with two different doses of the attenuated CV-777 strain and challenged with the same virulent PEDV strain three weeks later. The vaccinated pigs were partially protected against the challenge, and 25% of the low dose- and 50% of the high dose-exposed pigs did not shed virus after challenge.

Since winter of 2010, China experienced severe PED outbreaks with devastating damage to the swine industry. These outbreaks can be explained by re-emergence of new PEDV strains. To answer industry demand, Chinese researchers have developed a bivalent (PEDV and TGEV) attenuated vaccine that contained the PEDV strain ZJ08 (G1-b) and a bivalent attenuated vaccine based on the AJ1102 strain (G2-b). Inactivated bivalent vaccine based on the G2-b strain has also been developed. These vaccines are currently under clinical evaluation ([@bib0325]).

In Japan, PEDV strain 83P-5 (G1-a) was attenuated after 100 passages in Vero cells ([@bib0285]). Subsequently, this strain has been employed as an intramuscular (IM) live attenuated vaccine (P--5 V) in Japan and South Korea. In addition, two South Korean virulent PEDV strains (SM98-1 and DR-13) were attenuated by serial cell culture passages. The attenuated SM98-1 strain has been used as an IM live or killed vaccine, whereas DR-13 was used as an oral live vaccine. This oral vaccine was registered and commercialised in the Philippines in 2011. In South Korea, the multiple dose vaccination program (3 or 4 IM vaccinations in the following order: live-killed--killed or live-live-killed-killed, respectively) at 2- or 3-week intervals starting before farrowing is commonly recommended in pregnant sows ([@bib0165]).

According to a South Korean study, the administration of commercial vaccines increased the survival rate of piglets challenged with a virulent wild-type PEDV from 18.2% to over 80%. However, all vaccines did not significantly reduce morbidity rate and virus shedding ([@bib0165]). Also, Song et al. ([@bib0305]) reported 60% reduction of the mortality rate of the suckling piglets born to the sows that were IM vaccinated with DR-13 PEDV vaccine.

Despite of nationwide use of commercially available vaccines, South Korea experienced a devastated PED epidemic in 2013--2014. PEDV G2-b strains were responsible for recent severe PED epidemics in Asian countries and North America. Considering this fact, South Korean researchers ([@bib0010]) tested an inactivated vaccine based on serially cultured G2-b strain KOR/KNU-141112/2014. Pregnant sows were immunized IM with the inactivated adjuvanted vaccine at 6 and 3 weeks prior to farrowing. Six-day old piglets were challenged with the homologous virulent virus. Piglets born to vaccinated sows had reduced morbidity, mortality and quickly recovered daily weight gain. Further studies are needed to evaluate efficacy of this vaccine in 1- or 2-day old piglets under field conditions.

All commercially available vaccines that are in use in Asia are traditional live attenuated or killed vaccines. However, researchers are working on the next-generation vaccines for PEDV ([Table 1](#tbl0005){ref-type="table"}). For instance, Hou et al. ([@bib0115]) expressed the PEDV N protein on the surface of lactobacillus. Oral and intranasal inoculations of recombinant *L. casei* into pregnant sow and mice resulted in high levels of N-specific serum IgG and mucosal IgA. Similarly, Liu et al. ([@bib0175]) expressed S1 and N protein in recombinant *L. casei* and reported enhanced mucosal and systemic immune responses after oral immunization of mice. Meng et al. ([@bib0195]) evaluated the immunogenicity of recombinant DNA plasmids expressing S genes from PEDV and TGEV in mice. The results showed that the recombinant DNA plasmids increased the proliferation of T lymphocytes and the number of CD4+ and CD8+ T lymphocytes. In addition, the DNA vaccines induced a high level of IFN-γ in the immunized mice. At 35 days post-immunization, the recombinant DNA plasmids bearing full-length S genes of TGEV and PEDV stimulated high levels of virus-neutralizing antibodies. Zhang et al. ([@bib0375]) have also constructed bivalent DNA vaccine co-expressing S genes of TGEV and PEDV. Attenuated *Salmonella* Typhimurium was used for oral delivery this vaccine into pigs. Vaccinated pigs developed TGEV and PEDV-specific cellular and humoral immune responses; however, challenge experiment was not conducted in this study.

There have also been reports on expressing recombinant PEDV S protein fragments in plants ([@bib0005]) and in a cell line ([@bib0225]). Feeding mice with transgenic tobacco plants that express the S protein fragment containing the PEDV neutralizing epitope induced PEDV-specific antibody and cell-mediated immune responses. In another study, Oh et al. ([@bib0225]) established porcine cell line stably expressing S1 fragment of the PEDV spike protein. Pregnant sows were immunized IM 3 times with the purified and adjuvanted protein 6, 4 and 2 weeks prior to farrowing. The sows developed PEDV-specific neutralizing antibody response in serum and colostrum. One 4- to 5-day-old piglet was selected randomly from each farrowing sow for challenge with virulent PEDV. The piglets born to vaccinated sows showed reduced morbidity, mortality and virus shedding. However, a low number of challenged piglets hamper the author's conclusion about efficient protection of neonatal piglets.

7. Future perspectives {#sec0035}
======================

With the disappearance of TGEV around the world, the need for TGEV vaccines has dropped over the last few years. For North America and Europe, only two major international animal health companies continue to offer TGEV vaccines. In contrast, many parts of Asia including China and Korea are still dealing with TGEV outbreaks, and different types of vaccines are still available. The introduction of PEDV into the North American herd in 2013--2014, however, has reversed this picture and has highlighted the global need for effective vaccines. Coronaviruses represent an important group of animal pathogens that can have devastating impacts in a variety of species. For an industry to rely on biosecurity alone seems somewhat risky and, in case of an emerging disease, can lead to major economic losses, as witnessed in North America over the last two years. Indeed, the phylogeny of coronaviruses demonstrates a great deal of diversity in antigenic variants, which may lead to limited cross-protection against infection with different strains. Thus, it is important to continue to survey novel PEDV variants that may emerge locally or globally through antigenic drift (point mutations) or antigenic shift (recombination events).

Effective prevention and control of PEDV and other coronaviruses can only be achieved through the use of vaccines. An ideal vaccine prevents mortality and clinical disease in newborn piglets, the age group most seriously affected by the disease, as well as viral shedding. As lactogenic immunity is a key mechanism of protection, efforts to enhance the levels of antibodies in the milk through formulation (adjuvants) and delivery (mucosal) are critical. However, time is also of essence when dealing with a new strain, as traditional manufacturing vaccine methods like virus isolation, inactivation or attenuation can be time-consuming. Therefore, research on next-generation vaccines such as RNA particle, DNA, sub-unit and viral-vectored approaches is critical for the prevention of future outbreaks of emerging coronavirus diseases.

Conflict of interest statement {#sec0040}
==============================

The authors declare no conflict of interest.
